Tarextumab
Monoclonal antibody
- none
- Investigational
- 1359940-55-8
- none
- 333YMY788E
- D11775
Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer.[1] Two early stage clinical trials have reported encouraging results.[1]
See also
- Notch signaling pathway, e.g. in embryo tissue development
References
- ^ a b "Tarextumab Gets FDA Orphan Drug Designation for Lung, Pancreatic Cancer". 2015.
- v
- t
- e